Welcome!

News Feed Item

2013 US Hospital Cancer Diagnostics Market

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

2013 US Hospital Cancer Diagnostics Market

http://www.reportlinker.com/p01079355/2013-US-Hospital-Cancer-Diagnostics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

This new report from Venture Planning Group contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: 

  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals.  
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of  leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers. 

         Contains 567 pages and 50 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Brest Cancer

2. Lung Cancer

3. Colon and Rectum Cancer

4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

- ADA

- B-Protein

- PNP

- 5'-Nucleotidase

27. Oncogenes

- Abl/abl-bcr

- AIB1

- BCL-2

- BRCA1

- CD44

- C-fos

- C-myb

- C-myc

- CYP-17

- Erb-B

- HPC1

- N-myc

- P40

- P51

- P53

- PIK3CA

- PTI-1

- Ras

- Reg

- Sis

- Src

28. Polypeptide Growth Factors

- Basic Fibroblast Growth Factor

- Beta-TGF

- Cachectin (TNT)

- Calmodulin

- ECFR

- Nerve Growth Factor (NGF)

- Epidermal Growth Factor (EGF)

- Ornithine Decarboxylase

- Transferrin

- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon

- B Cell Growth Factors

- B Cell Growth Factor (BCGF)

- Gamma-Interferon

- Interleukin-1 (IL-1)

- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine

- Actin

- Alpha-Actin

- Antineuronal Antibodies

- 7B2

- B72.3

- Bax

- BCD-F9

- BLCA-4

- Blood Group Antigens A,B,H

- CA 50

- CA 72-4/TAG-72

- CA 195

- CA-242

- CA-549

- CAM 26

- CAR-3

- Cathepsin-D

- Chromogranin A and B

- Cluster 1 Antigen

- Cluster-5/5A Antigen

- CTA

- CU18

- DR-70

- DU-PAN-2

- Endometrial Bleeding Associated Factor

- Endostatin

- Epithelial Membrane Antigen

- Feulgen Hydrolysis

- Fibronectin

- FSH

- (1->3)-L-fucosyltransferase

- Gastrin-Releasing Peptide (GRP)

- GDCFP-15

- Glucagon

- Glycoamines

- H23

- Her-2

- Human Carcinoma Antigen

- HPA

- HSP27

- Intermediate Filaments

- Cytokeratins/CK18/Cyfra 21-1

- Desmin

- Gliofibrillary Acid Protein

- Neurofilaments

- Vimentin

- KA 93

- Kinases

- KP16D3

- LAI

- Leukocyte Common Antigen

- Lewis Antigens

- Lysophosphatidic Acid (LPA)

- Ma 695/Ma 552

- MABDF3

- MAG

- ME1

- Minactivin

- MN/CA9

- MSA

- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor 1

- Myosin

- NEA-130

- NMP22

- OA-519

- Opiod Peptides

- P-glycoprotein

- Pancreatic Oncofetal Antigen (POA)

- Placental Lactogen

- PR92

- Proliferative Index, Ki-67

- Px

- RB Inactivation/Deletion

- Ret

- SCCL 175

- Selectin

- Sialic Acid

- Sialyl SSEA-1/SLX

- SN10

- Somatostatin

- TA-90

- TABA

- Tachykinin

- TAG 12

- TPS

- Troponin

- Tubulin

- VCAM

- VEGF

- Villen

C. Instrumentation Review

And Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

- PCR

- DAP-PCR

- Immuno-PCR

- QC-PCR

- CAR

- DNA

- HPA

- LCR

- NASBA

- QBR

- SDA

- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Industry Consolidation

4. Managed Care

5. Hospitals

6. Admissions

7. Length of Stay

8. Industry Diversification

9. Physician Demographics

10. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

11. Laboratory Regulations

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Point-Of-Care Testing

d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Dako

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Otho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

List of Tables

Tumor Marker Classification

Major Companies Developing or Marketing

ACTH Tests

Major Companies Developing or Marketing

AFP Tests

Major Companies Developing or Marketing

Beta-2 Microglobulin Tests

Major Companies Developing or Marketing

CA 15-3/27.29 Tests

Major Companies Developing or Marketing

CA 19-9 Tests

Major Companies Developing or Marketing

CA 125 Tests

Major Companies Developing or Marketing

Calcitonin Tests

Major Companies Developing or Marketing

CEA Tests

Major Companies Developing or Marketing

Estrogen Receptor Tests

Major Companies Developing or Marketing

Progesterone Receptor Tests

Major Companies Developing or Marketing

Ferritin Tests

Major Companies Developing or Marketing

Gastrin Tests

Major Companies Developing or Marketing

HCG Tests

Major Companies Developing or Marketing

Insulin Tests

Major Companies Developing or Marketing

NSE Tests

Major Companies Developing or Marketing

Occult Blood Tests

Major Companies Developing or Marketing

PAP Smear/HPV Tests

Major Companies Developing or Marketing

PAP Tests

Major Companies Developing or Marketing

PSA Tests

Major Companies Developing or Marketing

Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications

In Cancer Diagnosis

Oncogenes Potential Applications

In Cancer Diagnosis

Major Companies Developing or Marketing

Oncogene Tests

Growth Factors Potential Applications

In Cancer Diagnosis

Colony Stimulating Factors Potential

Applications in Cancer Diagnosis

Lymphokines Potential Applications

In Cancer Diagnosis

Immunohistochemical Stains Potential

Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital

Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates

Per 100,000 Population

U.S., Laboratories Performing Cancer Diagnostic

Tests

U.S., Hospital Laboratories Performing

Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer

Diagnostic Test Volume Forecast by Test

U.S., Total Cancer Diagnostics Sales

By Major Supplier

U.S., ACTH Testing Market Diagnostics

Sales by Major Supplier

U.S., AFP Testing Market Diagnostics

Sales by Major Supplier

U.S., Beta-2 Migroblolulin Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 15-3/27.29 Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 19-9 Testing Market Diagnostics

Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics

Sales by Major Supplier

U.S., CEA Testing Market Diagnostics

Sales by Major Supplier

U.S., Ferritin Testing Market

Diagnostics Sales by Major Supplier

U.S., HCG Testing Market

Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market

Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing

Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics

Sales by Major Supplier

U.S., Progesterone Receptor Testing Market

Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics

Sales by Major Supplier

To order this report:

Diagnostics Industry: 2013 US Hospital Cancer Diagnostics Market

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Pulzze Systems was happy to participate in such a premier event and thankful to be receiving the winning investment and global network support from G-Startup Worldwide. It is an exciting time for Pulzze to showcase the effectiveness of innovative technologies and enable them to make the world smarter and better. The reputable contest is held to identify promising startups around the globe that are assured to change the world through their innovative products and disruptive technologies. There w...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...